Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1975 Mar;55(3):487–499. doi: 10.1172/JCI107955

Osteogenic sarcoma. Immunologic parameters before and during immunotherapy with tumor-specific transfer factor.

A S Levin, V S Byers, H H Fudenberg, J Wybran, A J Hackett, J O Johnston, L E Spitler
PMCID: PMC301776  PMID: 1078826

Abstract

18 patients with osteogenic sarcoma were followed by serial measurements in vitro of tumor-specific cell-mediated cytotoxicity and of "active" and total rosette-forming T-cells. 13 of these patients have had or are currently receiving injections of osteogenic sarcoma-specific dialyzable transfer factor derived from healthy donors. In three patients with very small lesions, cytotoxicity was high before amputation and decreased within 2 mo after removal of tumor. Cytotoxicity was low at time of diagnosis in all patients with large tumor masses. The cytotoxicity of the patients' lymphocytes increased after administration of tumor-specific transfer factor in all patients so treated. Patients receiving nonspecific transfer factor showed evidence of declining cell-mediated cytotoxicity. Tumor-specific transfer factor may produce an increase in cell-mediated cytotoxicity to the tumor in patients with osteogenic sarcoma. This possibility is suggested by the pain and edema that occurred in the area of the tumor in patients who had metastatic disease when therapy was started and by lymphocytic infiltrates in the tumor, as well as by the increase in cell-mediated cytotoxicity and the increase in percentage of active rosette-forming cells from subnormal to normal. Serial measurements of cell-mediated cytotoxicity are helpful in monitoring the efficacy of transfer factor and other modes of therapy in these patients, and these measurements are the best available criteria for selection of donors of tumor-specific transfer factor.

Full text

PDF
487

Images in this article

490Image
on p.490
492Image
on p.492
493Image
on p.493
494Image
on p.494

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Byers V. S., Levin A. S., Hackett A. J., Fudenberg H. H. Tumor-specific cell-mediated immunity in household contacts of cancer patients.. J Clin Invest. 1975 Mar;55(3):500–513. doi: 10.1172/JCI107956. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Cinader B. The future of tumor immunology. Med Clin North Am. 1972 May;56(3):801–836. doi: 10.1016/s0025-7125(16)32394-x. [DOI] [PubMed] [Google Scholar]
  3. Fisher B. The present status of tumor immunology. Adv Surg. 1971;5:189–254. [PubMed] [Google Scholar]
  4. Jaffe N. Recent advances in the chemotherapy of metastatic osteogenic sarcoma. Cancer. 1972 Dec;30(6):1627–1631. doi: 10.1002/1097-0142(197212)30:6<1627::aid-cncr2820300631>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  5. LAWRENCE H. S. The transfer in humans of delayed skin sensitivity to streptococcal M substance and to tuberculin with disrupted leucocytes. J Clin Invest. 1955 Feb;34(2):219–230. doi: 10.1172/JCI103075. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Lawrence H. S. Transfer factor. Adv Immunol. 1969;11:195–266. doi: 10.1016/s0065-2776(08)60480-0. [DOI] [PubMed] [Google Scholar]
  7. Levin A. S., Fudenberg H. H., Hopper J. E., Wilson S. K., Nisonoff A. Immunofluorescent evidence for cellular control of synthesis of variable regions of light and heavy chains of immunoglobulins G and M by the same gene. Proc Natl Acad Sci U S A. 1971 Jan;68(1):169–171. doi: 10.1073/pnas.68.1.169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Levin A. S., Spitler L. E., Stites D. P., Fudenberg H. H. Wiskott-Aldrich syndrome, a genetically determined cellular immunologic deficiency: clinical and laboratory responses to therapy with transfer factor. Proc Natl Acad Sci U S A. 1970 Oct;67(2):821–828. doi: 10.1073/pnas.67.2.821. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. LoBuglio A. F., Neidhart J. A., Hilberg R. W., Metz E. N., Balcerzak S. P. The effect of transfer factor therapy on tumor immunity in alveolar soft part sarcoma. Cell Immunol. 1973 Apr;7(1):159–165. doi: 10.1016/0008-8749(73)90192-5. [DOI] [PubMed] [Google Scholar]
  10. O'Bryan R. M., Luce J. K., Talley R. W., Gottlieb J. A., Baker L. H., Bonadonna G. Phase II evaluation of adriamycin in human neoplasia. Cancer. 1973 Jul;32(1):1–8. doi: 10.1002/1097-0142(197307)32:1<1::aid-cncr2820320101>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  11. Owens R. B. Glandular epithelial cells from mice: a method for selective cultivation. J Natl Cancer Inst. 1974 Apr;52(4):1375–1378. doi: 10.1093/jnci/52.4.1375. [DOI] [PubMed] [Google Scholar]
  12. Perlmann P., Perlmann H., Biberfeld P. Specifically cytotoxic lymphocytes produced by preincubation with antibody-complexed target cells. J Immunol. 1972 Feb;108(2):558–561. [PubMed] [Google Scholar]
  13. Price C. H., Jeffree G. M. Metastatic spread of osteosarcoma. Br J Cancer. 1973 Dec;28(6):515–524. doi: 10.1038/bjc.1973.181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Smith R. T. Possibilities and problems of immunologic intervention in cancer. N Engl J Med. 1972 Aug 31;287(9):439–450. doi: 10.1056/NEJM197208312870905. [DOI] [PubMed] [Google Scholar]
  15. Spitler L. E., Levin A. S., Stites D. P., Fudenberg H. H., Pirofsky B., August C. S., Stiehm E. R., Hitzig W. H., Gatti R. A. The Wiskott-Aldrich syndrome. Results of transfer factor therapy. J Clin Invest. 1972 Dec;51(12):3216–3224. doi: 10.1172/JCI107148. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Wybran J., Fudenberg H. H. Thymus-derived rosette-forming cells in various human disease states: cancer, lymphoma, bacterial and viral infections, and other diseases. J Clin Invest. 1973 May;52(5):1026–1032. doi: 10.1172/JCI107267. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Wybran J., Fudenberg H. H. Thymus-derived rosette-forming cells. N Engl J Med. 1973 May 17;288(20):1072–1073. doi: 10.1056/NEJM197305172882011. [DOI] [PubMed] [Google Scholar]
  18. Wybran J., Levin A. S., Spitler L. E., Fudenberg H. H. Rosette-forming cells, immunologic deficiency diseases and transfer factor. N Engl J Med. 1973 Apr 5;288(14):710–713. doi: 10.1056/NEJM197304052881405. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES